An update on male hypogonadism therapy
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. AREAS COVERED: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. EXPERT OPINION: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 2×
“Hypogonadism diagnosed based on serum total testosterone levels was estimated to be < 5% in men aged between 20 -- 30 years, 12% in men 50 -- 60 years, and between 19 and 49% in men aged 60 -- 80 years in the Baltimore Longitudinal Study of Aging [4].”
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 10×
“, 400 -- 700 ng/dl) and resolution or reduction in symptoms of hypogonadism [1].”
InfluentialSelf-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 4×
“If the serum testosterone is over 370 ng/dl (12 nmol/l), it is unlikely the subject is hypogonadal [6] unless the patient has a very high sex hormone binding globulin (SHBG) resulting in low free or bioavailable testosterone.”
InfluentialAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 3×
“In recent years it is recognized that serum testosterone levels measured in different laboratories even using similar methodology have large interlaboratory variations [17-20].”
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 2×
“However, in another study in US veterans with low testosterone levels who had undergone coronary angiography, testosterone replacement therapy was associated with an increase in risks of myocardial infarction, ischemic stroke and all-cause mortality [15].”
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“Studies have shown that testosterone may have a threshold effect on some parameters such as sexual function but there appears to be a dose-related response to testosterone treatment for muscle mass, fat mass and hemoglobin and hematocrit [26,27].”
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 2×
“Many of these factors can be modified by lifestyle changes or disease-specific interventions to prevent age-related decline in testosterone [11].”
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Cited by
Testosterone and Cardiovascular Disease
Kloner, R. A., Carson, C., Dobs, A., Kopecky, S., & Mohler, E. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.005 · Cited by 371
Clomiphene citrate for men with hypogonadism: a systematic review and meta‐analysis
Huijben, M., Lock, M. T. W. T., de Kemp, V. F., de Kort, L. M. O., & van Breda, H. M. K. (2022) · Andrology · doi:10.1111/andr.13146 · Cited by 65
Santos, H. O., & Teixeira, F. J. (2020) · The Aging Male · doi:10.1080/13685538.2019.1573220 · Cited by 41
“symptoms, such as very low T levels and azoospermia, the primary therapy should be hormonal replacement with T and/or hCG [42,62].”
BackgroundNovel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31
Oxytocin intranasal administration as a new hope for hypogonadotropic hypogonadism patients
Salehi, M. S., Pandamooz, S., & Khazali, H. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.09.020 · Cited by 5
“In addition, exogenous testosterone can potentially increase the risk of prostate disease [4] and develop acne and oiliness of skin because of the androgenic effects on sebaceous gland [3].”
Background
Metadata
- Authors
- Surampudi, P., Swerdloff, R. S., & Wang, C.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-04-23
- Volume
- 15
- Issue
- 9
- Pages
- 1247-1264
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2038766557
- Cited by
- 45
- References
- 67
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on male hypogonadism therapy. https://app.cochat.ai/papers/10.1517/14656566.2014.913022
- The paper
- Surampudi, P., Swerdloff, R. S., & Wang, C. (2014). An update on male hypogonadism therapy. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.913022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.